BridgeBio Pharma, Inc. secured a $1 billion preferred equity investment from leading global investment firms Sixth Street and KKR. The financing is intended to enhance BridgeBio's financial position, providing capital to support the commercialization of its drug acoramidis, approved as Attruby in the U.S. and BEYONTTRA in Europe and Japan, for transthyretin amyloid cardiomyopathy (ATTR-CM).
This capital injection will also support the continued development and acceleration of BridgeBio's broader pipeline of genetic medicines. The investment demonstrates significant confidence from top-tier institutional investors in BridgeBio's commercial strategy for acoramidis and the potential of its R&D engine, which focuses on addressing a range of genetic diseases.
The preferred equity structure provides BridgeBio with less-dilutive capital compared to traditional equity offerings, enabling the company to maintain substantial shareholder upside while gaining crucial financial flexibility. This strategic funding is expected to play a vital role in BridgeBio's long-term growth and its mission to bring innovative therapies to patients with genetic diseases.
